 | Up a level |
Hoffmeister, A; Mayerle, J; Beglinger, C; Büchler, M W; Bufler, P; Dathe, K; Fölsch, U R; Friess, H; Izbicki, J; Kahl, S; Klar, E; Keller, J; Knoefel, W T; Layer, P; Loehr, M; Meier, R; Riemann, J F; Rünzi, M; Schmid, R M; Schreyer, A; ... (2015). English language version of the S3-consensus guidelines on chronic pancreatitis: Definition, aetiology, diagnostic examinations, medical, endoscopic and surgical management of chronic pancreatitis. Zeitschrift für Gastroenterologie, 53(12), pp. 1447-1495. Thieme 10.1055/s-0041-107379
Rogler, G; Beglinger, C; Mottet, C; Seibold, F; Gross, V (2011). [Topical therapy of ulcerative colitis]. Praxis - schweizerische Rundschau für Medizin, 100(23), pp. 1413-24. Bern: Huber 10.1024/1661-8157/a000722
Straumann, A; Conus, S; Grzonka, P; Kita, H; Kephart, G; Bussmann, C; Beglinger, C; Smith, D A; Patel, J; Byrne, M; Simon, H-U (2010). Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial. Gut, 59(1), pp. 21-30. London: BMJ Publishing Group 10.1136/gut.2009.178558
Pittet, V; Juillerat, P; Michetti, P; Vader, J-P; Burnand, B; Rogler, G; Beglinger, C; Seibold, F; Mottet, C; Felley, C; Gonvers, J-J; Froehlich, F; Swiss IBD Cohort Study Group, The (2010). Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Alimentary pharmacology & therapeutics, 32(8), pp. 1007-16. Oxford: Wiley-Blackwell 10.1111/j.1365-2036.2010.04434.x
Schoepfer, AM; Beglinger, C; Straumann, A; Trummler, M; Renzulli, P; Seibold, F (2009). Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflammatory bowel diseases, 15(12), pp. 1851-1858. Hagerstown, Md.: Lippincott Williams & Wilkins 10.1002/ibd.20986
Beglinger, C; Binek, J; Braegger, C; Michetti, P; Rogler, G; Sauter, B; Seibold, F; Straumann, A (2008). Infliximab Monotherapie versus Kombinationstherapie mit Immunmodulatoren. Medical journal TMJ - Schweizer Zeitschrift für Innere Medizin(1), pp. 32-33. Neuhausen (CH): Rosenfluh
Beglinger, C; Dudler, J; Mottet, C; Nicod, L; Seibold, F; Villiger, P; Zellweger, J (2007). Screening for tuberculosis infection before the initiation of an anti-TNF-alpha therapy. Swiss medical weekly(137), 620-2 A. Muttenz: EMH Schweizerischer Ärzteverlag
Bauerfeind, P; Beglinger, C; Beltinger, J; Braegger, C; Eigenmann, F; Fried, M; Guyot, J; Hürlimann, R; Michetti, P; Seibold, F; Straumann, A (2006). Infliximab - Recommendations practiques pour le traitment de la maladie de Crohn. Revue médicale suisse, 2(74), pp. 1807-15. Genève: Médecine & Hygiène
